Ardelyx (ARDX) vs Ginkgo Bioworks (DNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed Ardelyx (ARDX) over the past year, losing 29.5% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -97.6% for DNA. Ginkgo Bioworks is the larger company by market cap ($881.5 million vs $846.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | DNA |
|---|---|---|
| Share price | $3.28 | $13.09 |
| Market cap | $846.86M | $881.48M |
| 1-day change | +0.31% | +15.43% |
| YTD return | -43.91% | +36.46% |
| 1-year return | -35.38% | -29.52% |
| 5-year return | +202.78% | -97.62% |
| Forward P/E | 11.29 | — |
| EPS (TTM) | $-0.23 | $-5.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $18.22 |
| 52-week low | $3.18 | $5.37 |
| Distance from 52-week high | -60.95% | -28.16% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +293.29% | -46.52% |
| Average volume | 4.17M | 1.80M |
| Shares outstanding | 258.19M | 55.38M |
| Employees | 489 | 485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
ARDX vs DNA FAQ
Which is bigger, Ardelyx or Ginkgo Bioworks?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $881.48M compared with $846.86M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or DNA?
DNA returned -29.52% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Ginkgo Bioworks in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Ardelyx and Biotechnology: Biological Products (No Diagnostic Substances) for Ginkgo Bioworks.